Latest news with #AnnualShareholdersMeeting
Yahoo
8 hours ago
- Business
- Yahoo
MiNK Therapeutics Announces Virtual Annual Shareholders Meeting
NEW YORK, June 10, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic, off-the-shelf invariant natural killer T (iNKT) cell therapies, today announced that its Annual Shareholders Meeting will begin at 9:30 a.m. ET. on June 18, 2025, and will be conducted in a virtual format only. Registration for attendees will start at 9:15 a.m. ET. To participate in the Annual Shareholders Meeting, shareholders should visit and enter the 16-digit control number found in their proxy materials. Guests may also access the meeting in listen-only mode. No control number is required for guests. Webcast Information: Date: Wednesday, June 18, 2025 Time: 9:30 a.m. ET A live webcast and replay will be accessible from the Company's website at and at About MiNK Therapeutics MiNK Therapeutics is a clinical-stage biopharmaceutical company pioneering the development of allogeneic invariant natural killer T (iNKT) cell therapies and precision-targeted immune technologies. MiNK's proprietary platform is designed to restore immune balance and drive cytotoxic immune responses across cancer, immune-mediated diseases, and pulmonary immune failure. MiNK's lead asset, AGENT-797, is an off-the-shelf, allogeneic iNKT cell therapy currently in clinical development for the treatment of graft-versus-host disease (GvHD), solid tumors, and critical pulmonary immune collapse. MiNK is also advancing a pipeline of T cell receptor (TCR)-based therapies and neoantigen discovery tools that enable tumor- and tissue-specific immune activation with broad potential application. With a scalable, cryopreserved manufacturing process and a differentiated mechanism that bridges innate and adaptive immunity, MiNK is committed to developing next-generation immune reconstitution therapies that are accessible, durable, and applicable across a wide range of indications. For more information, visit or @MiNK_iNKT. Information that may be important to investors will be routinely posted on our website and social media channels. Investor Contact917-362-1370 investor@ Media Contact781-674-4428communications@ in to access your portfolio
Business Wire
8 hours ago
- Business
- Business Wire
Agenus Announces Virtual Annual Shareholders Meeting
LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. ('Agenus') (NASDAQ: AGEN), a leader in immuno-oncology innovation, today announced that its Annual Shareholders Meeting will begin at 10:30 a.m. ET on June 17, 2025, and will be conducted in a virtual format only. Registration for attendees will start at 10:15 a.m. ET. To participate in the Annual Shareholders Meeting, shareholders should visit and enter the 16-digit control number found in their proxy materials. Guests may also access the Annual Shareholders Meeting, but in listen-only mode. No control number is required for guests. Webcast Information: Time: 10:30 a.m. ET A live webcast and replay will be accessible on the Company's website at and at Voting Information: Shareholders of Agenus as of the April 24th, 2025, record date can vote. Alliance Advisors, Agenus's proxy solicitor, can assist shareholders with voting at 844-202-6561 or AGEN@ About Agenus Agenus is a leading immuno-oncology company targeting cancer with a comprehensive pipeline of immunological agents. The company was founded in 1994 with a mission to expand patient populations benefiting from cancer immunotherapy through combination approaches, using a broad repertoire of antibody therapeutics, adoptive cell therapies (through MiNK Therapeutics) and adjuvants (through SaponiQx). Agenus has robust end-to-end development capabilities, across commercial and clinical cGMP manufacturing facilities, research and discovery, and a global clinical operations footprint. Agenus is headquartered in Lexington, MA. For more information, visit or @agenus_bio. Information that may be important to investors will be routinely posted on our website and social media channels.
Yahoo
8 hours ago
- Business
- Yahoo
Agenus Announces Virtual Annual Shareholders Meeting
LEXINGTON, Mass., June 10, 2025--(BUSINESS WIRE)--Agenus Inc. ("Agenus") (NASDAQ: AGEN), a leader in immuno-oncology innovation, today announced that its Annual Shareholders Meeting will begin at 10:30 a.m. ET on June 17, 2025, and will be conducted in a virtual format only. Registration for attendees will start at 10:15 a.m. ET. To participate in the Annual Shareholders Meeting, shareholders should visit and enter the 16-digit control number found in their proxy materials. Guests may also access the Annual Shareholders Meeting, but in listen-only mode. No control number is required for guests. Webcast Information: Date: Tuesday, June 17, 2025 Time: 10:30 a.m. ET A live webcast and replay will be accessible on the Company's website at and at Voting Information: Shareholders of Agenus as of the April 24th, 2025, record date can vote. Alliance Advisors, Agenus's proxy solicitor, can assist shareholders with voting at 844-202-6561 or AGEN@ About Agenus Agenus is a leading immuno-oncology company targeting cancer with a comprehensive pipeline of immunological agents. The company was founded in 1994 with a mission to expand patient populations benefiting from cancer immunotherapy through combination approaches, using a broad repertoire of antibody therapeutics, adoptive cell therapies (through MiNK Therapeutics) and adjuvants (through SaponiQx). Agenus has robust end-to-end development capabilities, across commercial and clinical cGMP manufacturing facilities, research and discovery, and a global clinical operations footprint. Agenus is headquartered in Lexington, MA. For more information, visit or @agenus_bio. Information that may be important to investors will be routinely posted on our website and social media channels. View source version on Contacts Investors 917-362-1370investor@ Media 781-674-4422communications@
Yahoo
23-05-2025
- Business
- Yahoo
BIC: Remuneration of Non-Executive Corporate Officer
Publication in accordance with recommendation 26-1 of the AFEP-MEDEF Code of Corporate Governance for listed companies and in application of article L.22-10-13 of the French Commercial CodeClichy, France – May 23, 2025 – In its meeting of May 20, 2025, under the chairmanship of Edouard Bich, the Board of Directors of Société BIC, upon the recommendation of the Remuneration Committee, decided the following: REMUNERATION FOR THE FISCAL YEAR 2025 Following the nomination of Edouard Bich as Chair of the Board of Directors, it was decided to modify the fixed annual remuneration of the Chair with effect May 20, 2025. The annual fixed remuneration will return to its previous level of 300,000 euros per year, versus 400,000 euros voted at the Annual General Meeting on May 20, 2025. The Company specifies that this change remains in line with the remuneration policy approved by shareholders at the Annual Shareholders Meeting held on May 20, 2025. This remuneration remains exclusively fixed, in accordance with best governance practices and the recommendations of the AFEP-MEDEF Code. The 2025 Remuneration Policy, voted under Resolution 14 during the Annual Shareholders Meeting of May 20, 2025 remains applicable to Nikos Koumettis, Chair of the Board for the period from January 1 to May 20, 2025. Under the provisions of articles L.22-10-34 II and L.22-10-8 of the French Commercial Code, the payment of these amounts is contingent on a positive vote of the Annual Shareholders Meeting to be held in 2026 (ex-post vote). Contacts Brice ParisVP Investor Relations +33 6 42 87 54 Investor Bethridge ToovellVP Group Communications +1 917 821 Isabelle de Segonzac Image 7, Press Relations +33 6 89 87 61 39isegonzac@ Agenda All dates are to be confirmed H1 2025 results July 30th, 2025 Q3 2025 net sales October 28th, 2025 Full Year 2025 results February 24th, 2026 About BIC BIC is a world leader in stationery, lighters, and shavers. Its vision: to bring simplicity and joy to everyday life. For 80 years, BIC's commitment to providing high-quality, affordable, and reliable products has made BIC a symbol of reliability and innovation. Present in more than 160 countries and with more than 13,000 employees worldwide, BIC brings together iconic brands and products such as BIC® 4-Colors™, BodyMark®, Cello®, Cristal®, Inkbox®, BIC Kids®, Lucky™, Rocketbook®, Tattly®, Tipp-Ex®, Wite-Out®, Djeep®, EZ Load™, EZ Reach®, BIC® Flex™, Soleil®, Tangle Teezer®, and many others. Listed on Euronext Paris and included in the SBF 120 and CAC Mid 60 indices, BIC is also recognized for its unwavering commitment to sustainability and education. To learn more, visit and to discover the full range of BIC products, visit Follow BIC on LinkedIn, Instagram, YouTube and TikTok. Attachment BIC_CP_Post AGM_Chair Remuneration_21MAY25_VENGSign in to access your portfolio
Yahoo
16-05-2025
- Automotive
- Yahoo
Michelin: Annual Shareholders Meeting of May 16, 2024
Clermont-Ferrand – May 16, 2025 COMPAGNIE GÉNÉRALE DES ÉTABLISSEMENTS MICHELIN Annual Shareholders Meeting of May 16, 2025 The Annual Shareholders Meeting of the Michelin Group was held today in Clermont-Ferrand under the chairmanship of Florent Menegaux, Managing Chairman. The event was webcast live on the Company's website All of the resolutions submitted for shareholder approval were adopted, including, in particular: the payment of a dividend of €1.38 per share, payable in cash as from May 23, 2025; the re-election to the Supervisory Board of Wolf-Henning Scheider, who was also re-appointed by the Board to the Audit and Corporate Social Responsibility Committees, of which he was already a member; and the 2024 compensation packages and 2025 compensation policy for the Managers and members of the Supervisory Board. At the 2025 Annual Shareholders Meeting, Florent Menegaux spoke of the Company's need for agility in the face of recent crises and the importance of the "Michelin in Motion 2030" strategy for anticipating and absorbing shocks. He highlighted the transformations needed to prepare Michelin for the decades ahead, focusing on employee development, customer experience, innovation, data use, agile operating methods, and protecting the planet. The innovation power of the Michelin Group was demonstrated in various ways during the meeting. A preview presentation was given on the new MICHELIN CrossClimate 3 and MICHELIN CrossClimate 3 Sport tires, which show how the Group continues to rise to technological challenges. Shareholders were able to learn about the scope of activities of the Manufacture des Talents, a concrete example of the Group's social innovation work. Serving as a major university for over 130,000 students in Clermont-Ferrand, the campus is open to Michelin employees as well as employees from other companies and public organizations. Shareholders then attended a presentation on an airless tire, an innovation-packed solution capable of withstanding extreme conditions and designed to fit out a lunar roving vehicle as part of NASA's ARTEMIS program. Lastly, Florent Menegaux concluded the Annual Meeting by looking back at the deployment of the "Michelin in Motion 2030" strategy, reviewing the progress made in 2024: « Our "Michelin in Motion 2030" strategy provides us with a clear, relevant roadmap, reducing our dependence on the fluctuations of a single market. In the face of successive crises, from COVID to international instability, we are continuing to develop in the composite solutions sector, offering unique experiences for our customers while also transforming the Group to prepare for the future. The Manufacture des Talents illustrates our ambition to develop employees, and our obsession with customer experience remains central to our value creation strategy. Lastly, Michelin's capacity for innovation continues to be deployed in many areas, with more than 10 new product ranges launched and 245 patents filed last year, demonstrating the commitment of the Group and its teams to offering ever more proactive, innovative solutions ».For more information, you can find vote totals on the resolutions, answers to written questions, and a webcast of the entire Annual Meeting on the corporate website Investor calendar May 21, 2025 Ex-dividend date May 23, 2025 Dividend payment date July 24, 2025 First-half 2025 results October 22, 2025 Quarterly information for the nine months ending September 30, 2025 Contacts Investor Relationsinvestor-relations@ Media Relations+33 (0) 1 45 66 22 Shareholders+33 (0) 4 73 32 23 05Muriel Elisabete DISCLAIMERThis press release is not an offer to purchase or a solicitation to recommend the purchase of Michelin shares. To obtain more detailed information on Michelin, please consult the documents filed in France with the Autorité des Marchés Financiers, which are also available from the press release may contain a number of forward-looking statements. Although the Company believes that these statements are based on reasonable assumptions as at the time of publishing this document, they are by nature subject to risks and contingencies liable to translate into a difference between actual data and the forecasts made or inferred by these statements Attachment 20250516_PR AGM 2025_ENG
